Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: Systematic review and meta-analysis of randomized controlled trials

BJU International

Volumn 111, Issue 2, 2013, Pages 304-311

  Kahokehr, Arman ^a   Vather, Ryash ^b   Nixon, Anthony ^a   Hill, Andrew G ^b  

^a WHANGAREI HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

benign prostatic hyperplasia; cyclo oxygenase; inflammation; lower urinary tract symptoms; non steroidal anti inflammatory drugs; prostate

Indexed keywords

CELECOXIB; DOXAZOSIN; FINASTERIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; TENOXICAM;

ARTICLE; COMPUTER PROGRAM; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; META ANALYSIS; MICTURITION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URODYNAMICS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINATION;

EID: 84873171297     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11559.x     Document Type: Article

References (34)

1. McVary KT,. BPH: epidemiology and comorbidities. Am J Manag Care 2006; 12 (5 Suppl.): S122-128
2. Fitzpatrick JM,. The natural history of benign prostatic hyperplasia. BJU Int 2006; 97 (Suppl. 2): 3-6; discussion 21-2
3. Di Silverio F, Gentile V, De Matteis A, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003; 43: 164-175
4. Kohnen PW, Drach GW,. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol 1979; 121: 755-760
5. Schenk JM, Kristal AR, Neuhouser ML, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 2010; 171: 571-582
6. Roehrborn CG, Kaplan SA, Noble WD, et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS study. J Urol Suppl 2005; 173: abstract 1277
7. Steiner GE, Newman ME, Paikl D, et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003; 56: 171-182
8. Wang W, Bergh A, Damber JE,. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 2004; 61: 60-72
9. Minnery CH, Getzenberg RH,. Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and Ibuprofen. J Urol 2005; 174: 375-379
10. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med 2009; 6: e1000097
11. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12
12. Higgins JPT, Green S, eds. Cochrane Handbook for Systemic Review of Interventions. Version 5.0.1. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org
13. Higgins J, Green S,. Cochrane handbook for systemic review of interventions the cochrane collaboration. In, Higgins JPT, Green S, eds, Version 5.0.1; 2008. In Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [Updated September 2009], The Cochrane Collaboration, 2009. Available at: www.cochrane-handbook.org. Accessed November 2011
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
15. Di Silverio F, Bosman C, Salvatori M, et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol 2005; 47: 72-78; discussion 78-9
16. Falahatkar S, Mokhtari G, Pourreza F, Asgari SA, Kamran AN,. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology 2008; 72: 813-816
17. Ozdemir I, Bozkurt O, Demir O, Aslan G, Esen AA,. Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. Urology 2009; 74: 431-435
18. Kramer G, Mitteregger D, Marberger M,. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007; 51: 1202-1216
19. Theyer G, Kramer G, Assmann I, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992; 66: 96-107
20. Kramer G, Marberger M,. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006; 16: 25-29
21. Kramer G, Steiner GE, Handisurya A, et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002; 52: 43-58
22. Ponniah S, Arah I, Alexander RB,. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate 2000; 44: 49-54
23. Nickel JC, Downey J, Young I, Boag S,. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999; 84: 976-981
24. Huang X, Lee C,. Regulation of stromal proliferation, growth arrest, differentiation and apoptosis in benign prostatic hyperplasia by TGF-β. Front Biosci 2003; 8: s740-749
25. Kwak C, Jin RJ, Lee C, Park MS, Lee SE,. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int 2002; 89: 303-309
26. Fitchev PP, Wcislak SM, Lee C, et al. Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation. Lab Invest 2010; 90: 1078-1090
27. Erol H, Beder N, Caliskan T, Dundar M, Unsal A, Culhaci N,. Can the effect of antibiotherapy and anti-inflammatory therapy on serum PSA levels discriminate between benign and malign prostatic pathologies? Urol Int 2006; 76: 20-26
28. Jacobson S, Jacobson D, McGree ME, et al. Non-steroidal anti-inflammatory drugs and changes in serum benign prostatic specific antigen levels. J Urol Suppl 2009; 181 (Suppl. 4) (Abstract 1655): 596-597
29. Gray MA, Delahunt B, Fowles JR, Weinstein P, Cookes RR, Nacey JN,. Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives. Anticancer Res 2004; 24: 2069-2072
30. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW,. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41
31. Mahmud SM, Franco EL, Aprikian AG,. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 2010; 127: 1680-1691
32. Verhamme KM, Dieleman JP, Van Wijk MA, et al. Nonsteroidal anti-inflammatory drugs and increased risk of acute urinary retention. Arch Intern Med 2005; 165: 1547-1551
33. Joshi GP, Gertler R, Fricker R,. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs. Anesth Analg 2007; 105: 1793-1804. table of contents
34. de Leval X, Hanson J, David JL, Masereel B, Pirotte B, Dogne JM,. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Curr Med Chem 2004; 11: 1243-1252